셀렉티스(ADR)(CLLS)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.53 (+4.79%), 시가총액 $357.17M, 52주 범위 $1.33 ~ $5.35.
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
셀렉티스(ADR)의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
셀렉티스(ADR)의 현재 주가는 $1.53 (+4.79%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
셀렉티스(ADR)의 시가총액은 약 $357.17M입니다.
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of…